anticancer pro-soft drugs (Arisaph/Fox Chase)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nameanticancer pro-soft drugs (Arisaph/Fox Chase)
Drug Alias NameFAP-activated proteasome inhibitor (Arisaph)ARI-3996ARI-3099DOXARI-6000
ClassificationSmall molecules
Mechanisms of ActionVirus DNA polymerase inhibitorsTopoisomerase II inhibitorsProteasome inhibitors
TargetsProteasomeTopoisomerase IIVirus DNA polymerase
Therapy Area/IndicationsNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesArisaph Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArisaph Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksN/A